Satya Pharma Innovations
Transformative Precision Medicines
Satya is a pre-clinical stage precision medicine oncology company, focused on discovery and development of targeted therapeutics for unmet medical conditions. We work on therapeutics with a potential to be first-in-class and/ or best-in-class. Our targets span DNA damage response, oncogenes and other targeted approaches.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Satya Pharma Innovations
Transformative Precision Medicines
Satya is a pre-clinical stage precision medicine oncology company, focused on discovery and development of targeted therapeutics for unmet medical conditions. We work on therapeutics with a potential to be first-in-class and/ or best-in-class. Our targets span DNA damage response, oncogenes and other targeted approaches.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Science
Precision oncology targets to build a portfolio of assets
in DDR and oncogenic pathways
Satya is building a portfolio of therapeutics targeting novel biological pathways including oncogenes, DDR pathways and synthetic lethal targets.
Targets are chosen for specific patient populations that can be uniquely addressed using bio-marker identification strategies as well as PD markers that can be followed both pre-clinically and in the clinic.
Satya is building a portfolio of therapeutics targeting novel biological pathways including oncogenes, DDR pathways and synthetic lethal targets.
Targets are chosen for specific patient populations that can be uniquely addressed using bio-marker identification strategies as well as PD markers that can be followed both pre-clinically and in the clinic.
Science
Precision oncology targets to build a portfolio of assets
in DDR and oncogenic pathways
Satya is building a portfolio of therapeutics targeting novel biological pathways including oncogenes, DDR pathways and synthetic lethal targets.
Targets are chosen for specific patient populations that can be uniquely addressed using bio-marker identification strategies as well as PD markers that can be followed both pre-clinically and in the clinic.
Satya is building a portfolio of therapeutics targeting novel biological pathways including oncogenes, DDR pathways and synthetic lethal targets.
Targets are chosen for specific patient populations that can be uniquely addressed using bio-marker identification strategies as well as PD markers that can be followed both pre-clinically and in the clinic.
TEAM
Leadership
Advisory Board
Satya’s Scientific Advisory Board comprises seasoned and accomplished
scientists, with preclinical and clinical expertise in oncology.
scientists, with preclinical and clinical expertise in oncology.
Satya’s Scientific Advisory Board comprises seasoned and accomplished scientists, with preclinical and clinical expertise in oncology.
Pipeline
Satya’s Pipeline comprises First-In-Class and Best-In-Class
Targets focused on DDR pathway and Oncogenes.
Targets focused on DDR pathway and Oncogenes.
TARGET
MOA / INDICATION
BIO MARKER
RIGHTS
EARLY DISCOVERY
LEAD OPTIMIZATION
PRE - CLINICAL
IND
RAD51
DDR; TNBC, NSCLC, PAN Ca
Replication Stress, Oncogene mutations
Global
87%
SOS1
Oncogene; NSCLC, CRC
EGFR mutation & Pan RAS mutation
Global
76%
Undisclosed
DDR/Oncogene
Undisclosed
Partnered
Undisclosed
KIF18A
DDR
CIN+ve cells
Global
35%
PARG
DDR
HRD
Global
13%
USP1
DDR
HRD
Global
9%
Pipeline
Satya’s Pipeline comprises First-In-Class and Best-In-Class
Targets focused on DDR pathway and Oncogenes.
Targets focused on DDR pathway and Oncogenes.
Satya’s Pipeline comprises First-In-Class and Best-In-Class Targets focused
on DDR pathway and Oncogenes.
TARGET
MOA / INDICATION
BIO MARKER
RIGHTS
EARLY DISCOVERY
LEAD OPTIMIZATION
PRE - CLINICAL
IND
RAD51
DDR; TNBC, NSCLC, PAN Ca
Replication Stress, Oncogene mutations
Global
91%
SOS1
Oncogene; NSCLC, CRC
EGFR mutation & Pan RAS mutation
Global
77%
Undisclosed
DDR/Oncogene
Undisclosed
Partnered
Undisclosed
KIF18A
DDR
CIN+ve cells
Global
25%
PARG
DDR
HRD
Global
11%
USP1
DDR
HRD
Global
11%
Pipeline
Satya’s Pipeline comprises First-In-Class and Best-In-Class Targets focused on DDR pathway and Oncogenes.
Previous
Next
Recent highlights on our programs, News, Events and Leadership
Satya is at BIO, 2023 – Boston, June 3-6
Satya is attending the BIO at Boston during June 3-6, 2023. Please also visit the
June 2, 2023
Satya chosen as one of the top Promising startups at BIO ASIA 2023
BIO ASIA 2023 held in February 2023 Satya is chosen as one of the most
February 26, 2023
